{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:09:17Z","timestamp":1793830157292,"version":"4.6.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009757","name":"H.K.H. Kronprinsessan Lovisas F\u00f6rening f\u00f6r Barnasjukv\u00e5rd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009757","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005701","name":"\u00c5hl\u00e9n-stiftelsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005701","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Marcus Bergvalls Stiftelse"},{"DOI":"10.13039\/100010799","name":"Stiftelsen Tysta Skolan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010799","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009810","name":"Wera Ekstr\u00f6ms Stiftelse f\u00f6r Pediatrisk Forskning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009810","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gun & Bertil Stohens Stiftelse"},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n                    , the pneumococcus, is a cause of major illness globally. Invasive pneumococcal disease (IPD) is characterized by pneumococci invading blood (bacteremia), lungs (pneumonia), or brain and cerebrospinal fluid (meningitis). Meningitis remains an important global health concern because half of the survivors experience long-term neurological damage. The antibiotics commonly used to treat pneumococcal infections are \u03b2-lactams and macrolides, however,\n                    <jats:italic>S. pneumoniae<\/jats:italic>\n                    is nowadays often resistant to one or several antibiotics, therefore novel antimicrobials are needed. Here, we found that the bacteriophage-derived cpl-1 endolysin showed consistent antibacterial activity against \u03b2-lactam- and macrolide-resistant pneumococcal clinical strains grown in human blood and human cerebrospinal fluid. Exploiting synergistic and additive mechanisms, supplementation of cpl-1 to either penicillin or erythromycin, as representatives for \u03b2-lactam and macrolide antibiotics, rescued human neuronal cells from the cytotoxicity of antibiotic-resistant pneumococcal infections. Finally, systemic administration of cpl-1 supplemented to penicillin in mice infected with penicillin-resistant pneumococci successfully reduced bacteremia, and, thanks to the efficient penetration across the blood\u2013brain barrier, abolished bacterial load in the brain, resulting in increased (89%) survival accompanied by an asymptomatic course of infection. These findings strongly suggest that cpl-1 can enhance antibiotic susceptibility in \u03b2-lactam- and macrolide-resistant\n                    <jats:italic>S. pneumoniae<\/jats:italic>\n                    , serving as a valuable adjunct therapy to standard-of-care antibiotics for multidrug-resistant IPD.\n                  <\/jats:p>","DOI":"10.1186\/s10020-025-01226-1","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T06:40:51Z","timestamp":1746427251000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Bacteriophage-derived endolysins restore antibiotic susceptibility in \u03b2-lactam- and macrolide-resistant Streptococcus pneumoniae infections"],"prefix":"10.1186","volume":"31","author":[{"given":"Niels","family":"Vander Elst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Farmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Kn\u00f6rr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte","family":"Merlijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Iovino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"1226_CR1","unstructured":"2023 Antibacterial agents in clinical and preclinical development an overview and analysis. https:\/\/www.who.int\/publications\/i\/item\/9789240094000."},{"key":"1226_CR2","doi-asserted-by":"publisher","first-page":"101543","DOI":"10.1016\/j.mex.2021.101543","volume":"8","author":"P Bellio","year":"2021","unstructured":"Bellio P, Fagnani L, Nazzicone L, Celenza G. New and simplified method for drug combination studies by checkerboard assay. MethodsX. 2021;8:101543.","journal-title":"MethodsX."},{"key":"1226_CR3","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/j.1365-2958.2004.04446.x","volume":"55","author":"A Bera","year":"2005","unstructured":"Bera A, Herbert S, Jakob A, Vollmer W, G\u00f6tz F. Why are pathogenic staphylococci so lysozyme resistant? The peptidoglycan O-acetyltransferase OatA is the major determinant for lysozyme resistance of Staphylococcus aureus. Mol Microbiol. 2005;55:778\u201387.","journal-title":"Mol Microbiol"},{"key":"1226_CR4","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jbbm.2006.10.009","volume":"70","author":"Y Briers","year":"2007","unstructured":"Briers Y, Lavigne R, Volckaert G, Hertveldt K. A standardized approach for accurate quantification of murein hydrolase activity in high-throughput assays. J Biochem Biophys Methods. 2007;70:531\u20133.","journal-title":"J Biochem Biophys Methods"},{"key":"1226_CR5","unstructured":"Centers for Disease Control and Prevention. About pneumococcal vaccines. 2024a.\u00a0https:\/\/www.cdc.gov\/vaccines\/vpd\/pneumo\/hcp\/about-vaccine.html."},{"key":"1226_CR6","unstructured":"Centers for Disease Control and Prevention. Antibiotic-resistant Streptococcus pneumoniae. 2024b.\u00a0https:\/\/www.cdc.gov\/pneumococcal\/php\/drug-resistance\/index.html."},{"key":"1226_CR7","unstructured":"Centers for Disease Control and Prevention. Pneumococcal disease. 2024c.\u00a0https:\/\/www.cdc.gov\/pneumococcal\/about\/index.html."},{"key":"1226_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/INF.0b013e3181ef25f7","volume":"30","author":"A Chandran","year":"2011","unstructured":"Chandran A, Herbert H, Misurski D, Santosham M. Long-term sequelae of childhood bacterial meningitis: An underappreciated problem. Pediatr Infect Dis J. 2011;30:3\u20136.","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"1226_CR9","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1097\/MJT.0000000000000551","volume":"24","author":"R Cherazard","year":"2017","unstructured":"Cherazard R, et al. Antimicrobial resistant streptococcus pneumoniae: prevalence, mechanisms, and clinical implications. Am J Ther. 2017;24(3):e361\u20139 https:\/\/www.americantherapeutics.com.","journal-title":"Am J Ther."},{"key":"1226_CR10","doi-asserted-by":"publisher","first-page":"5355","DOI":"10.1128\/AAC.01372-13","volume":"57","author":"R D\u00edez-Mart\u00ednez","year":"2013","unstructured":"D\u00edez-Mart\u00ednez R, et al. Improving the lethal effect of Cpl-7, a pneumococcal phage lysozyme with broad bactericidal activity, by inverting the net charge of its cell wall-binding module. Antimicrob Agents Chemother. 2013;57:5355\u201365.","journal-title":"Antimicrob Agents Chemother"},{"key":"1226_CR11","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1093\/jac\/dkv038","volume":"70","author":"R D\u00edez-Mart\u00ednez","year":"2015","unstructured":"D\u00edez-Mart\u00ednez R, et al. A novel chimeric phage lysin with high in vitro and in vivo bactericidal activity against Streptococcus pneumoniae. J Antimicrob Chemother. 2015;70:1763\u201373.","journal-title":"J Antimicrob Chemother"},{"key":"1226_CR12","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1128\/AAC.49.3.1225-1228.2005","volume":"49","author":"S Djurkovic","year":"2005","unstructured":"Djurkovic S, Loeffler JM, Fischetti VA. Synergistic killing of Streptococcus pneumoniae with the bacteriophage lytic enzyme Cpl-1 and penicillin or gentamicin depends on the level of penicillin resistance. Antimicrob Agents Chemother. 2005;49:1225\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"1226_CR13","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1093\/jac\/dkt131","volume":"68","author":"JM Doehn","year":"2013","unstructured":"Doehn JM, et al. Delivery of the endolysin Cpl-1 by inhalation rescues mice with fatal pneumococcal pneumonia. J Antimicrob Chemother. 2013;68:2111\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"1226_CR14","doi-asserted-by":"publisher","first-page":"4789","DOI":"10.1128\/AAC.49.11.4789-4792.2005","volume":"49","author":"JM Entenza","year":"2005","unstructured":"Entenza JM, Loeffler JM, Grandgirard D, Fischetti VA, Moreillon P. Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats. Antimicrob Agents Chemother. 2005;49:4789\u201392.","journal-title":"Antimicrob Agents Chemother"},{"key":"1226_CR15","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1128\/AAC.45.4.1078-1085.2001","volume":"45","author":"H Erlendsdottir","year":"2001","unstructured":"Erlendsdottir H, et al. Penicillin pharmacodynamics in four experimental pneumococcal infection models. Antimicrob Agents Chemother. 2001;45:1078\u201385.","journal-title":"Antimicrob Agents Chemother"},{"key":"1226_CR16","unstructured":"EUCAST. Clinical breakpoints - breakpoints and guidance. 2024.\u00a0https:\/\/www.eucast.org\/clinical_breakpoints."},{"key":"1226_CR17","unstructured":"European Centre for Disease Prevention and Control. Factsheet for health professionals about pneumococcal disease. 2023.\u00a0https:\/\/www.ecdc.europa.eu\/en\/pneumococcal-disease\/facts."},{"key":"1226_CR18","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1086\/587942","volume":"197","author":"D Grandgirard","year":"2008","unstructured":"Grandgirard D, Loeffler JM, Fischetti VA, Leib SL. Phage lytic enzyme Cpl-1 for antibacterial therapy in experimental pneumococcal meningitis. J Infect Dis. 2008;197:1519\u201322.","journal-title":"J Infect Dis"},{"key":"1226_CR19","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s11908-010-0110-7","volume":"12","author":"N Hameed","year":"2010","unstructured":"Hameed N, Tunkel AR. Treatment of drug-resistant pneumococcal meningitis. Curr Infect Dis Rep. 2010;12:274\u201381.\u00a0Preprint at https:\/\/doi.org\/10.1007\/s11908-010-0110-7.","journal-title":"Curr Infect Dis Rep."},{"issue":"11","key":"1226_CR20","doi-asserted-by":"publisher","first-page":"638","DOI":"10.3390\/v10110638","volume":"10","author":"M Harhala","year":"2018","unstructured":"Harhala M, et al. Safety Studies of Pneumococcal Endolysins Cpl-1 and Pal. Viruses. 2018;10(11):638.","journal-title":"Viruses"},{"issue":"15","key":"1226_CR21","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1001\/jama.286.15.1857","volume":"286","author":"TB Hyde","year":"2001","unstructured":"Hyde TB, et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA. 2001;286(15):1857\u201362 https:\/\/www.jama.com.","journal-title":"JAMA."},{"issue":"10","key":"1226_CR22","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.3390\/nu11102265","volume":"11","author":"M Inazu","year":"2019","unstructured":"Inazu M. Functional expression of choline transporters in the blood-brain barrier. Nutrients. 2019;11(10):2265.","journal-title":"Nutrients."},{"key":"1226_CR23","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/mmi.14451","volume":"113","author":"F Iovino","year":"2020","unstructured":"Iovino F, Nannapaneni P, Henriques-Normark B, Normark S. The impact of the ancillary pilus-1 protein RrgA of Streptococcus pneumoniae on colonization and disease. Mol Microbiol. 2020;113:650\u20138.","journal-title":"Mol Microbiol"},{"key":"1226_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/978-1-4939-9199-0_14","volume":"1968","author":"F Iovino","year":"2019","unstructured":"Iovino F, Sender V, Henriques-Normark B. In Vivo Mouse Models to Study Pneumococcal Host Interaction and Invasive Pneumococcal Disease. Methods Mol Biol. 2019;1968:173\u201381.","journal-title":"Methods Mol Biol"},{"key":"1226_CR25","doi-asserted-by":"publisher","first-page":"100940","DOI":"10.1016\/j.lanmic.2024.07.003","volume":"5","author":"T Jesudason","year":"2024","unstructured":"Jesudason T. WHO publishes updated list of bacterial priority pathogens. Lancet Microbe. 2024;5:100940.","journal-title":"Lancet Microbe"},{"key":"1226_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S1473-3099(09)70306-8","volume":"10","author":"KS Kim","year":"2010","unstructured":"Kim KS. Acute bacterial meningitis in infants and children. Lancet Infect Dis. 2010;10:32\u201342.\u00a0Preprint at\u00a0https:\/\/doi.org\/10.1016\/S1473-3099(09)70306-8.","journal-title":"Lancet Infect Dis."},{"key":"1226_CR27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jinf.2016.04.009","volume":"73","author":"MJ Lucas","year":"2016","unstructured":"Lucas MJ, Brouwer MC, van de Beek D. Neurological sequelae of bacterial meningitis. J Infect. 2016;73:18\u201327.","journal-title":"J Infect"},{"issue":"9854","key":"1226_CR28","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1016\/S0140-6736(12)61187-8","volume":"380","author":"P Mcintyre","year":"2012","unstructured":"Mcintyre P, Mcintyre PB, O\u2019brien KL, Greenwood B, Van De Beek D. Effect of vaccines on bacterial meningitis worldwide. Lancet. 2012;380(9854):1703\u201311 https:\/\/www.thelancet.com.","journal-title":"Lancet."},{"key":"1226_CR29","doi-asserted-by":"publisher","first-page":"E2352402","DOI":"10.1001\/jamanetworkopen.2023.52402","volume":"7","author":"S Mohanty","year":"2024","unstructured":"Mohanty S, et al. Increased Risk of Long-Term Disabilities Following Childhood Bacterial Meningitis in Sweden. JAMA Netw Open. 2024;7:E2352402.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"1226_CR30","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3390\/v13040680","volume":"13","author":"E Murray","year":"2021","unstructured":"Murray E, Draper LA, Ross RP, Hill C. The advantages and challenges of using endolysins in a clinical setting. Viruses. 2021;13(4):680.","journal-title":"Viruses."},{"key":"1226_CR31","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1128\/CMR.00007-10","volume":"23","author":"R Nau","year":"2010","unstructured":"Nau R, S\u00f6rgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;23:858\u201383.\u00a0Preprint at\u00a0https:\/\/doi.org\/10.1128\/CMR.00007-10.","journal-title":"Clin Microbiol Rev."},{"key":"1226_CR32","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1128\/JCM.01778-16","volume":"55","author":"L Olarte","year":"2017","unstructured":"Olarte L, et al. Emergence of multidrug-resistant pneumococcal serotype 35B among children in the United States. J Clin Microbiol. 2017;55:724\u201334.","journal-title":"J Clin Microbiol"},{"issue":"1","key":"1226_CR33","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1186\/s12879-021-06470-4","volume":"21","author":"EM Rinc\u00f3n-L\u00f3pez","year":"2021","unstructured":"Rinc\u00f3n-L\u00f3pez EM, et al. Interleukin 6 as a marker of severe bacterial infection in children with sickle cell disease and fever: a case\u2013control study. BMC Infect Dis. 2021;21(1):741.","journal-title":"BMC Infect Dis."},{"issue":"1","key":"1226_CR34","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1186\/s12879-019-4618-7","volume":"19","author":"J Song","year":"2019","unstructured":"Song J, et al. Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: A prospective controlled study according to the Sepsis-3 definitions. BMC Infect Dis. 2019;19(1):968.","journal-title":"BMC Infect Dis."},{"key":"1226_CR35","doi-asserted-by":"publisher","first-page":"e1009432","DOI":"10.1371\/journal.ppat.1009432","volume":"17","author":"M Tabusi","year":"2021","unstructured":"Tabusi M, et al. Neuronal death in pneumococcal meningitis is triggered by pneumolysin and RrgA interactions with \u03b2-actin. PLoS Pathog. 2021;17:e1009432.","journal-title":"PLoS Pathog"},{"key":"1226_CR36","doi-asserted-by":"publisher","first-page":"e0266928","DOI":"10.1371\/journal.pone.0266928","volume":"17","author":"LG Valente","year":"2022","unstructured":"Valente LG, et al. Efficacy assessment of a novel endolysin PlyAZ3aT for the treatment of ceftriaxone-resistant pneumococcal meningitis in an infant rat model. PLoS ONE. 2022;17:e0266928.","journal-title":"PLoS ONE"},{"key":"1226_CR37","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S0140-6736(21)00883-7","volume":"398","author":"D van de Beek","year":"2021","unstructured":"van de Beek D, Brouwer MC, Koedel U, Wall EC. Community-acquired bacterial meningitis. Lancet. 2021;398:1171\u201383.\u00a0Preprint at\u00a0https:\/\/doi.org\/10.1016\/S0140-6736(21)00883-7.","journal-title":"Lancet."},{"key":"1226_CR38","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/j.cmi.2016.01.007","volume":"22","author":"D van de Beek","year":"2016","unstructured":"van de Beek D, et al. ESCMID guideline: Diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016;22:S37\u201362.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"1226_CR39","doi-asserted-by":"crossref","first-page":"181","DOI":"10.21825\/vdt.v87i4.16065","volume":"87","author":"N Vander Elst","year":"2018","unstructured":"Vander Elst N, Meyer E. Potential therapeutic application of bacteriophages and phage-derived endolysins as alternative treatment of bovine mastitis. Vlaams Diergeneeskundig Tijdschrift. 2018;87(4):181\u20137.","journal-title":"Vlaams Diergeneeskundig Tijdschrift."},{"issue":"1","key":"1226_CR40","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13028-024-00740-2","volume":"66","author":"N Vander Elst","year":"2024","unstructured":"Vander Elst N. Bacteriophage-derived endolysins as innovative antimicrobials against bovine mastitis-causing streptococci and staphylococci: a state-of-the-art review. Acta Vet Scand. 2024;66(1):20.\u00a0Preprint at\u00a0https:\/\/doi.org\/10.1186\/s13028-024-00740-2.","journal-title":"Acta Vet Scand."},{"issue":"1","key":"1226_CR41","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s00253-023-12820-w","volume":"108","author":"N Vander Elst","year":"2024","unstructured":"Vander Elst N, Bellemans J, Lavigne R, Briers Y, Meyer E. Endolysin NC5 improves early cloxacillin treatment in a mouse model of Streptococcus uberis mastitis. Appl Microbiol Biotechnol. 2024;108(1):118.","journal-title":"Appl Microbiol Biotechnol."},{"key":"1226_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antibiotics9090621","volume":"9","author":"N Vander Elst","year":"2020","unstructured":"Vander Elst N, et al. Characterization of the bacteriophage-derived endolysins plyss2 and plyss9 with in vitro lytic activity against bovine mastitis streptococcus uberis. Antibiotics. 2020;9:1\u201314.","journal-title":"Antibiotics."},{"key":"1226_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/1751-7915.14339","author":"N Vander Elst","year":"2023","unstructured":"Vander Elst N, et al. Development of engineered endolysins with in vitro intracellular activity against streptococcal bovine mastitis-causing pathogens. Microb Biotechnol. 2023. https:\/\/doi.org\/10.1111\/1751-7915.14339.","journal-title":"Microb Biotechnol"},{"key":"1226_CR44","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ijantimicag.2013.06.020","volume":"42","author":"J Vouillamoz","year":"2013","unstructured":"Vouillamoz J, et al. Bactericidal synergism between daptomycin and the phage lysin Cpl-1 in a mouse model of pneumococcal bacteraemia. Int J Antimicrob Agents. 2013;42:416\u201321.","journal-title":"Int J Antimicrob Agents"},{"key":"1226_CR45","unstructured":"World Health Organization. WHO bacterial priority pathogens list. 2024."},{"issue":"1","key":"1226_CR46","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12941-023-00653-4","volume":"22","author":"X Yang","year":"2023","unstructured":"Yang X, et al. PCT, IL-6, and IL-10 facilitate early diagnosis and pathogen classifications in bloodstream infection. Ann Clin Microbiol Antimicrob. 2023;22(1):103.","journal-title":"Ann Clin Microbiol Antimicrob."}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01226-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-025-01226-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01226-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:04:32Z","timestamp":1764180272000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.1186\/s10020-025-01226-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1226"],"URL":"https:\/\/doi.org\/10.1186\/s10020-025-01226-1","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]},"assertion":[{"value":"9 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal experiments were performed in accordance with Swedish legislation (Svenska jordbruksverket), and ethical approval (permit number 18965\u20132021).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NV declares issued and pending patent applications with regards to endolysin technology.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"170"}}